삼성서울병원

Ko En

Hematology-Oncology Kang, Won Ki M.D

Expertise
gastric cancer, colorectal cancer
Treament Schedule 04 月
DATE
MON
01
TUE
02
WEB
03
THU
04
FRI
05
SAT
06
SUN
07
MON
08
TUE
09
WEB
10
THU
11
FRI
12
SAT
13
SUN
14
MON
15
TUE
16
WEB
17
THU
18
FRI
19
SAT
20
SUN
21
MON
22
TUE
23
WEB
24
THU
25
FRI
26
SAT
27
SUN
28
MON
29
TUE
30
AM
PM
Treament Schedule 05 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM

Medical Education

Seoul National University College of Medicine

Post-Graduate Training

Fellowship   1990~1991 Division of Hematology-Oncology, Dept of Internal Medicine,Seoul National University Hospital
Residency   1987~1990 Dept. of Internal Medicine, Seoul National University Hospital
Internship   1983~1984 Seoul National University Hospital

Professional Appointments

2011~Present Director Gastric Cancer Center, Samsung Cancer Center
2005~2011 Deputy Director Samsung Cancer Center
2005~2009 Chief Division of Hematology-Oncology, Dept of Medicine Samsung Medical Center
2002~Present Professor Dept. of Medicine, Sungkyunkwan University School of Medicine
1997~2002 Assistant Professor Dept. of Medicine, Sungkyunkwan University School of Medicine
1994~1997 Staff Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center

Professional Memberships

Korean Cancer Association

Selected Publications

  • EUR RADIOL 2021 10.1007/s00330-021-08094-3 Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer Cha1, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D
    View PubMed
  • GASTRIC CANCER 2021 10.1007/s10120-021-01173-w Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Boku1, N; Satoh, T; Ryu, MH; Chao, Y; Kato, K; Chung, HC; Chen, JS; Muro, K; Kang, WK; Yeh, KH; Yoshikawa, T; Oh, SC; Bai, LY; Tamura, T; Lee, KW; Hamamoto, Y; Kim, JG; Chin, K; Oh, DY; Minashi, K; Cho, JY; Tsuda, M; Nishiyama, T; Chen, LT; Kang, YK
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/1758835921992992 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed